Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5,416
Completed, industry sponsors, Oncology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting2,031
- Completed5,416
5,416 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
Strand Therapeutics Inc.Industry
NCT06249048 · 39 participants · Start May 3, 2024 · Primary completion Jun 17, 2026
Drug: STX-001; Keytruda® · For: Advanced Solid Tumor
Sites: Scottsdale, Arizona; Beverly Hills, California; Cleveland, Ohio · 7 sites in all
- GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabPivotal-lookingCompleted
NETRIS PharmaIndustry
NCT04652076 · 238 participants · Start Dec 14, 2020 · Primary completion Oct 30, 2025
Drug: NP137; Pembrolizumab and 2 more · For: Endometrial Carcinoma; Cervix Carcinoma
Sites: Besançon, France; Bordeaux, France; Caen, France · 15 sites in all
- Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompleted
Suzhou Junde Biotechnology Co., LtdIndustry
NCT04843098 · 13 participants · Start May 26, 2021 · Primary completion Nov 20, 2024
Drug: TL117; Paclitaxel · For: Head and Neck Squamous Cell Carcinoma
Sites: Shanghai, China
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03005782 · 333 participants · Start Nov 7, 2016 · Primary completion Apr 2, 2024
Drug: REGN3767; cemiplimab · For: Malignancies
Sites: Encinitas, California; Fresno, California; La Jolla, California · 43 sites in all
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Industry
NCT03125746 · 24 participants · Start Jun 12, 2017 · Primary completion Jul 21, 2021
Drug: LXI-15029; LXI-15029+Exemestane · For: Advanced Breast Cancer
Sites: Beijing, China
- CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Completed
Vittoria BiotherapeuticsIndustry
NCT06420089 · 19 participants · Start Oct 4, 2024 · Primary completion Sep 24, 2026
Drug: Senza5 CART5 · For: T Cell Non-Hodgkin Lymphoma
Sites: New York, New York; Philadelphia, Pennsylvania
Corbus Pharmaceuticals Inc.Industry
NCT06603844 · 51 participants · Start Dec 4, 2024 · Primary completion Jan 30, 2026
Drug: CRB-601 monoclonal antibody; Anti-PD-1 monoclonal antibody · For: Solid Tumor
Sites: Birmingham, Alabama; Tucson, Arizona; La Jolla, California · 26 sites in all
Arvinas Inc.Industry
NCT07023731 · 76 participants · Start May 29, 2025 · Primary completion Oct 30, 2026
Drug: ARV-806 · For: KRAS G12D Mutation; Advanced Solid Cancer
Sites: Phoenix, Arizona; New Haven, Connecticut; Tampa, Florida · 14 sites in all
PureTechIndustry
NCT04666688 · 44 participants · Start Dec 11, 2020 · Primary completion Dec 12, 2024
Drug: LYT-200; Tislelizumab · For: Metastatic Cancer; Solid Tumor; Head and Neck Cancer
Sites: Los Angeles, California; Denver, Colorado; Sarasota, Florida · 13 sites in all
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05794477 · 16 participants · Start Apr 28, 2023 · Primary completion Aug 20, 2024
Drug: Adebrelimab; SHR-1802 and 2 more · For: Advanced Solid Tumor
Sites: Changsha, China
Ascentage Pharma Group Inc.Industry
NCT04001777 · 73 participants · Start Jul 4, 2019 · Primary completion May 27, 2025
Drug: APG-1252; Osimertinib Mesylate Tablets · For: EGFR Positive Non-small Cell Lung Cancer
Sites: Guangzhou, China; Zhengzhou, China; Changchun, China · 4 sites in all
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06806046 · 12 participants · Start Dec 20, 2024 · Primary completion Sep 23, 2026
Drug: M9140 · For: Solid Tumors; Colorectal Cancer
Sites: Beijing, China; Guangzhou, China; Hangzhou, China
BioXcel Therapeutics IncIndustry
NCT03910660 · 97 participants · Start Jun 10, 2019 · Primary completion Oct 31, 2023
Drug: Talabostat; Pembrolizumab · For: Prostate Cancer; Neuroendocrine Tumors; Small Cell Carcinoma
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 12 sites in all
Werewolf Therapeutics, Inc.Industry
NCT05479812 · 156 participants · Start Aug 15, 2022 · Primary completion Apr 22, 2026
Drug: WTX-124; pembrolizumab · For: Metastatic Solid Tumor; Advanced Solid Tumor
Sites: Scottsdale, Arizona; Tampa, Florida; Atlanta, Georgia · 14 sites in all
Sinotau Pharmaceutical GroupIndustry
NCT07149831 · 6 participants · Start Jun 7, 2025 · Primary completion Aug 3, 2025
Drug: Flotufolastat F-18 Injection · For: Prostate Cancer
Sites: Beijing, China
AVEO Pharmaceuticals, Inc.Industry
NCT05865535 · 24 participants · Start Jun 13, 2023 · Primary completion Aug 11, 2026
Drug: AV-380 · For: Cachexia
Sites: Beverly Hills, California; Lakewood, California; Newport Beach, California · 12 sites in all
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
EMD Serono Research & Development Institute, Inc.Industry
NCT04170153 · 161 participants · Start Dec 20, 2019 · Primary completion Oct 14, 2026
Drug: M1774; Niraparib · For: Metastatic or Locally Advanced Unresectable Solid Tumors
Sites: Boston, Massachusetts; Austin, Texas; Dallas, Texas · 16 sites in all
STORM Therapeutics LTDIndustry
NCT05584111 · 42 participants · Start Nov 15, 2022 · Primary completion Aug 30, 2024
Drug: STC-15 · For: Advanced Cancer; Advanced Solid Tumor; Cancer
Sites: Scottsdale, Arizona; Houston, Texas; San Antonio, Texas
Immorna Biotherapeutics, Inc.Industry
NCT05727839 · 19 participants · Start Feb 24, 2023 · Primary completion Sep 30, 2024
Drug: JCXH-211 Injection · For: Cutaneous Tumor; Malignant Solid Tumor
Sites: Washington D.C., District of Columbia; Guangdong, China
Chengdu SciMount Pharmatech Co., Ltd.Industry
NCT07922096 · 35 participants · Start Feb 1, 2024 · Primary completion Apr 30, 2026
Drug: SMP-656 Injection · For: HER2-Expressing Advanced Solid Tumors; HER2-Mutated Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Beijing, China; Fuzhou, China; Changchun, China · 5 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Completed
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06637423 · 35 participants · Start Dec 20, 2024 · Primary completion Sep 30, 2026
Drug: Sacituzumab tirumotecan; Rescue medication and 1 more · For: Non-Muscle Invasive Bladder Cancer
Sites: Bakersfield, California; Tampa, Florida; Chicago, Illinois · 13 sites in all
CRISPR Therapeutics AGIndustry
NCT05795595 · 19 participants · Start Mar 13, 2023 · Primary completion Sep 18, 2025
Drug: CTX131 · For: Clear Cell Renal Cell Carcinoma; Cervical Carcinoma; Esophageal Carcinoma and 2 more
Sites: Duarte, California; Chicago, Illinois; Boston, Massachusetts · 7 sites in all
CRISPR TherapeuticsIndustry
NCT06492304 · 12 participants · Start Aug 13, 2024 · Primary completion Mar 11, 2026
Drug: CTX131 · For: T Cell Lymphoma; B Cell Lymphoma; Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Stanford, California; Boston, Massachusetts · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.